SecBot SecBot
6-K ·Filed Jul 23, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001575872-26-000526
Notable filing: 6-K
Actionable Insight • Neutral

The filing contains no actionable information. Monitor for any subsequent disclosure of the exhibit content or other material events. The stock is likely to trade on broader sector trends and prior fundamentals rather than this filing.

DirectionNeutral
Confidencelow
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.80
T+0 close · Jul 23, 2026 · via day close
Latest settled
+9.32%
T+60 · $12.90
Vs SPY
+4.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $11.80entry
  2. T+1 · 4mo ago −0.08%α −0.19% · $11.79
  3. T+5 · 4mo ago +0.25%α −0.22% · $11.83
  4. T+20 · 3mo ago +2.63%α −0.68% · $12.11
  5. T+60 · 5w ago +9.32%α +4.77% · $12.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's filed a Form 6-K on July 23, 2026, submitting an intimation (Exhibit 99.1) to the SEC. The exhibit content is unavailable in the provided documents, and no material financial or operational disclosures are evident from the filing metadata. This appears to be a routine foreign private issuer report with no immediate stock-moving information.

Key Facts

  • Filed Form 6-K on July 23, 2026, as a report of foreign private issuer.
  • Exhibit 99.1 is referenced but its content is not readable in the provided documents.
  • No financial figures, guidance, or material events are disclosed in the filing text.
  • Prior annual report (20-F) filed May 29, 2026, was routine with no new material disclosures.

Financial Impact

No financial impact identified from the available filing content.

Risk Factors

  • Lack of exhibit content prevents full assessment of the filing's purpose.
  • Routine filings can occasionally precede material announcements, but no such indication is present here.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000526
Document: 0001575872-26-000526-index.html0001575872-26-000526
Document: 0001575872-26-000526.txt0001575872-26-000526

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026